174 related articles for article (PubMed ID: 33910157)
21. Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line.
Zhao F; Wang J; Yao L; Qin YT; Tuerxun N; Wang H; Jiang M; Hao JP
Hematology; 2021 Dec; 26(1):518-528. PubMed ID: 34314648
[TBL] [Abstract][Full Text] [Related]
22. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo.
Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S
Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734
[TBL] [Abstract][Full Text] [Related]
23. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures.
Cohen JR; Resnick DZ; Niewiadomski P; Dong H; Liau LM; Waschek JA
BMC Cancer; 2010 Dec; 10():676. PubMed ID: 21143927
[TBL] [Abstract][Full Text] [Related]
24. A NanoBRET-Based Binding Assay for Smoothened Allows Real-time Analysis of Ligand Binding and Distinction of Two Binding Sites for BODIPY-cyclopamine.
Kozielewicz P; Bowin CF; Turku A; Schulte G
Mol Pharmacol; 2020 Jan; 97(1):23-34. PubMed ID: 31707356
[TBL] [Abstract][Full Text] [Related]
25. Cyclopamine treatment of full-blown Hh/Ptch-associated RMS partially inhibits Hh/Ptch signaling, but not tumor growth.
Ecke I; Rosenberger A; Obenauer S; Dullin C; Aberger F; Kimmina S; Schweyer S; Hahn H
Mol Carcinog; 2008 May; 47(5):361-72. PubMed ID: 17963245
[TBL] [Abstract][Full Text] [Related]
26. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma
Zhu M; Wang H; Wang C; Fang Y; Zhu T; Zhao W; Dong X; Zhang X
Front Pharmacol; 2019; 10():89. PubMed ID: 30846937
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
Liu G; Xue D; Yang J; Wang J; Liu X; Huang W; Li J; Long YQ; Tan W; Zhang A
J Med Chem; 2016 Dec; 59(24):11050-11068. PubMed ID: 27736063
[TBL] [Abstract][Full Text] [Related]
28. Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Kang C; Han JH; Oh J; Kulkarni R; Zhou W; Ferreira D; Jang TS; Myung CS; Na M
J Nat Prod; 2015 Apr; 78(4):803-10. PubMed ID: 25835537
[TBL] [Abstract][Full Text] [Related]
29. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
30. Identification and mechanism of action of the acylguanidine MRT-83, a novel potent Smoothened antagonist.
Roudaut H; Traiffort E; Gorojankina T; Vincent L; Faure H; Schoenfelder A; Mann A; Manetti F; Solinas A; Taddei M; Ruat M
Mol Pharmacol; 2011 Mar; 79(3):453-60. PubMed ID: 21177415
[TBL] [Abstract][Full Text] [Related]
31. Regulation of hedgehog signaling by Myc-interacting zinc finger protein 1, Miz1.
Lu J; Chen M; Ren XR; Wang J; Lyerly HK; Barak L; Chen W
PLoS One; 2013; 8(5):e63353. PubMed ID: 23671675
[TBL] [Abstract][Full Text] [Related]
32. Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling.
Fan Q; Gu D; He M; Liu H; Sheng T; Xie G; Li CX; Zhang X; Wainwright B; Garrossian A; Garrossian M; Gardner D; Xie J
Chin J Cancer; 2011 Jul; 30(7):472-81. PubMed ID: 21718593
[TBL] [Abstract][Full Text] [Related]
33. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
34. Smoothened as a new therapeutic target for human osteosarcoma.
Hirotsu M; Setoguchi T; Sasaki H; Matsunoshita Y; Gao H; Nagao H; Kunigou O; Komiya S
Mol Cancer; 2010 Jan; 9():5. PubMed ID: 20067614
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
36. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
37. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
Cell Chem Biol; 2024 Feb; ():. PubMed ID: 38442710
[TBL] [Abstract][Full Text] [Related]
38. Cyclopamine bioactivity by extraction method from Veratrum californicum.
Turner MW; Cruz R; Mattos J; Baughman N; Elwell J; Fothergill J; Nielsen A; Brookhouse J; Bartlett A; Malek P; Pu X; King MD; McDougal OM
Bioorg Med Chem; 2016 Aug; 24(16):3752-7. PubMed ID: 27338657
[TBL] [Abstract][Full Text] [Related]
39. Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.
Duan F; Lin M; Li C; Ding X; Qian G; Zhang H; Ge S; Fan X; Li J
Cancer Biol Ther; 2014 May; 15(5):544-59. PubMed ID: 24553082
[TBL] [Abstract][Full Text] [Related]
40. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction.
Meyers-Needham M; Lewis JA; Gencer S; Sentelle RD; Saddoughi SA; Clarke CJ; Hannun YA; Norell H; da Palma TM; Nishimura M; Kraveka JM; Khavandgar Z; Murshed M; Cevik MO; Ogretmen B
Mol Cancer Ther; 2012 May; 11(5):1092-102. PubMed ID: 22452947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
